FLUVOXAMINE, (Z)-

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21F3N2O2
Molecular Weight	318.3346
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCCCC\C(=N\OCCN)C1=CC=C(C=C1)C(F)(F)F

InChI

InChIKey=CJOFXWAVKWHTFT-ZHZULCJRSA-N

InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14-

HIDE SMILES / InChI

Molecular Formula	C15H21F3N2O2
Molecular Weight	318.3346
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00176
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluvoxamine.html

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors. Fluvoxamine is used for management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa. Fluvoxamine is known under the brand names: Faverin, Fevarin, Floxyfral, Dumyrox and Luvox.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin transporter 183 Target ID: CHEMBL228 Sources: http://www.drugbank.ca/drugs/DB00176	Inhibitor 8504
Cytochrome P450 19A1 39 Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26162595	Inhibitor 8504	7.84 µM [IC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24855828	Inhibitor 8504	0.29 µM [Ki]
Cytochrome P450 2D6 62 Target ID: CHEMBL289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21722088	Inhibitor 8504	13.4 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obsessive-compulsive disorder 33 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021519lbl.pdf	Primary		Approved 8583	LUVOX Approved Use LUVOX Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM-III-R. Launch Date 2007

C_max

Value	Dose	Analyte	Population
6.7 ng/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
4.2 ng/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
5.7 ng/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.8 ng/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
51 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
17 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
30 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
36 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
39 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
25 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18 μg/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
69.6 ng × h/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
43.9 ng × h/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
59.4 ng × h/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
155.1 ng × h/mL/kg DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
845 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
264 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
279 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
652 μg × min/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
860 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
201 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
195 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1338 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
495 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
315 μg × h/L REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
15.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
15 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
16 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13 h REVIEW https://link.springer.com/article/10.2165/00003088-199427030-00002	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FLUVOXAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		FLUVOXAMINE MALEATE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.5 g single, oral Overdose Dose: 5.5 g Route: oral Route: single Dose: 5.5 g Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/	Disc. AE: Sinus bradycardia, Fatigue... AEs leading to discontinuation/dose reduction: Sinus bradycardia (grade 3) Fatigue (grade 3) Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/
9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	Disc. AE: Drowsiness... AEs leading to discontinuation/dose reduction: Drowsiness Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
9.6 g single, oral Overdose Dose: 9.6 g Route: oral Route: single Dose: 9.6 g Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/	Disc. AE: Status epilepticus, Cardiac arrest... AEs leading to discontinuation/dose reduction: Status epilepticus Cardiac arrest Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/
4800 mg single, oral Overdose Dose: 4800 mg Route: oral Route: single Dose: 4800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea Abdominal pain Diarrhoea Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16160624/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16160624/	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (2.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/16160624/
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Disc. AE: Suicidal behavior, Serotonin syndrome... AEs leading to discontinuation/dose reduction: Suicidal behavior Serotonin syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
9.6 g single, oral Overdose Dose: 9.6 g Route: oral Route: single Dose: 9.6 g Sources: https://pubmed.ncbi.nlm.nih.gov/17952747	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/17952747	Other AEs: Status epilepticus... Other AEs: Status epilepticus Sources: https://pubmed.ncbi.nlm.nih.gov/17952747
4.8 g single, oral Overdose Dose: 4.8 g Route: oral Route: single Dose: 4.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/7906658	Other AEs: Abdominal pain, Nausea... Other AEs: Abdominal pain Nausea Diarrhoea Sources: https://pubmed.ncbi.nlm.nih.gov/7906658
300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Disc. AE: Suicidal ideation, Serotonin syndrome... Other AEs: Hypomania... AEs leading to discontinuation/dose reduction: Suicidal ideation Serotonin syndrome Seizures Hyponatremia Other AEs: Hypomania Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Disc. AE: Nausea, Insomnia... AEs leading to discontinuation/dose reduction: Nausea (9%) Insomnia (4%) Somnolence (4%) Headache (3%) Asthenia (2%) Vomiting (2%) Nervousness (2%) Agitation (2%) Dizziness (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 P-gp 1741	P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2D6 2546	inhibitor 4027 Sources: https://link.springer.com/article/10.2165/00003495-200060040-00006	weak
CYP1A2 2333	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/000629529390272X	yes [Ki 0.12 uM]	yes (co-administration study) Comment: The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in 10 healthy male subjects. Tizanidine Cmax was increased approximately 12-fold (range 5- fold to 32-fold), elimination half-life was increased by almost 3-fold, and AUC increased 33-fold (range 14- fold to 103-fold). Sources: https://www.sciencedirect.com/science/article/abs/pii/000629529390272X
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021519s012lbl.pdf#page=9 Page: 9.0	yes
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021519s012lbl.pdf#page=9 Page: 9.0	yes
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/	yes
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021519s012lbl.pdf#page=9 Page: 9.0	yes	yes (co-administration study) Comment: . In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg to 200 mg a day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentration (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021519s012lbl.pdf#page=9 Page: 9.0

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1388	substrate 4014 Sources: https://www.tandfonline.com/doi/abs/10.1080/00498250600718464	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268186/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY114043	https://www.001chemical.com/chem/61718-82-9
3B Scientific (Wuhan) Corp	3B3-052004	http://www.3bsc.com/index/pro_info.php?id=90280
AA Blocks	AA00IAU3	https://www.aablocks.com/goods/Goods/detail?id=AA00IAU3
Aaron Chemicals	AR00IBLV	http://www.aaronchem.com/61718-82-9
abcr GmbH	AB505781	http://www.abcr.de/shop/en/AB505781
Acadechem	ACDC-063925	http://acadechemical.com/product/6021
Achemtek	0104-021333	http://www.achemtek.com/61718-82-9
AHH Chemical co.,ltd	MT-51872	http://www.ahhchemical.com/product/MT-51872.html
AK Scientific, Inc. (AKSCI)	67924	http://www.aksci.com/item_detail.php?cat=67924
AK Scientific, Inc. (AKSCI)	J90043	http://www.aksci.com/item_detail.php?cat=J90043
Alfa Chemistry	AP61718829-A	https://reagents.alfa-chemistry.com/product/fluvoxamine-maleate-cas-61718-82-9-14127.html
Alfa Chemistry	AP61718829-B	https://reagents.alfa-chemistry.com/product/fluvoxamine-maleate-cas-61718-82-9-14128.html
Alsachim	930	http://www.alsachim.com/product-C2839-glo.bal-view.html
Ambeed	A771257	https://www.ambeed.com/products/61718-82-9.html
Ambinter	Amb15691917	http://www.ambinter.com/reference/15691917
Ambinter	Amb2444032	http://www.ambinter.com/reference/2444032
Angene	AGN-PC-0T1FVG	http://www.angenechemical.com/productshow/AGN-PC-0T1FVG.html
Anward	ANW-64083	http://www.anward.com/pro_result/50534
Ark Pharm	AK-51736	http://www.arkpharminc.com/products/61718-82-9.html
Aurora Fine Chemicals LLC	A13.108.176	http://online.aurorafinechemicals.com/info?ID=A13.108.176
Aurum Pharmatech LLC	NE47064	http://www.Aurumpharmatech.com/Product/ProductDetails/NE47064
AvaChem Scientific	2799	http://www.avachem.com/productSearch.asp?2799
BioChemPartner	BCP06470	http://www.biochempartner.com/61718-82-9-BCP06470
BioCrick	BCC1215	http://www.biocrick.com/Fluvoxamine-maleate-BCC1215.html
BLD Pharm	BD16087	http://www.bldpharm.com/products/61718-82-9.html
BOC Sciences	61718-82-9	https://www.bocsci.com/fluvoxamine-maleate-cas-61718-82-9-item-84-73281.html
Chem Scene	CS-1839	http://www.chemscene.com/61718-82-9.html
Chemenu	CM110029	http://www.chemenu.com/products/CM110029
ChemMol	30102974	http://www.chemmol.com/chemmol/30102974.html
ChemMol	44002360	http://www.chemmol.com/chemmol/44002360.html
ChemMol	97900565	http://www.chemmol.com/chemmol/97900565.html
ChemShuttle	151413	http://www.chemshuttle.com/catalogsearch/result/?q=61718-82-9&cat=
Chemspace	CSSB00000695070	https://chem-space.com/CSSB00000695070
Chemspace	CSSB00016999329	https://chem-space.com/CSSB00016999329
Chemspace	CSSB00020615146	https://chem-space.com/CSSB00020615146
Chemspace	CSSB00159245923	https://chem-space.com/CSSB00159245923
Clearsynth	CS-O-05780	http://www.clearsynth.com/en/CSO05780.html
Clearsynth	CS-O-06634	http://www.clearsynth.com/en/CSO06634.html
Clearsynth	CS-O-30921	https://www.clearsynth.com/en/CSO30921.html
Combi-Blocks	QH-5087	http://www.combi-blocks.com/cgi-bin/find.cgi?QH-5087
CSNpharm	CSN12312	https://www.csnpharm.com/products/fluvoxamine-maleate.html
DC Chemicals	DC9139	http://www.dcchemicals.com/product_show-Fluvoxamine_maleate.html
Enamine	Z1583164922	https://www.enaminestore.com/catalog/Z1583164922
Finetech	FT-0626496	http://www.finetechnology-ind.com/prod/detail/pub/61718-82-9.html
Glentham Life Sciences	GP8417	http://www.glentham.com/products/product/GP8417/
Hairui	HR100162	http://www.hairuichem.com/en/product/61718-82-9.html
Hairui	HR126565	http://www.hairuichem.com/en/product/54739-18-3.html
Hello Bio	HB2138	http://www.hellobio.com/fluvoxamine-maleate.html
iChemical	EBD19367	http://www.ichemical.com/chemicals/cas-61718-82-9
Lab Network	LN00193865	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00193865
LGC Standards	MM0058.00	https://www.lgcstandards.com/US/en/p/MM0058.00
Matrix Scientific	94691	https://www.matrixscientific.com/094691.html
mcule	MCULE-4841680762	https://mcule.com/MCULE-4841680762/
MedChem Express	HY-B0103A	https://www.medchemexpress.com/Fluvoxamine-maleate.html
Molcore	MC114043	https://www.molcore.com/product/61718-82-9
Molcore	MC559791	https://www.molcore.com/product/54739-18-3
MolPort	MolPort-002-885-827	https://www.molport.com/shop/molecule-link/MolPort-002-885-827
MolPort	MolPort-003-666-870	https://www.molport.com/shop/molecule-link/MolPort-003-666-870
MolPort	MolPort-044-175-494	https://www.molport.com/shop/molecule-link/MolPort-044-175-494
MolPort	MolPort-046-682-876	https://www.molport.com/shop/molecule-link/MolPort-046-682-876
MuseChem	A000443	https://www.musechem.com/product/A000443.html
Oakwood	245750	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=167600&ExtHyperLink=1
OChem	6991	http://www.ocheminc.com/index.php?act=psearch&pid=739F183
Parchem	29005	http://www.parchem.com/chemical-supplier-distributor/Fluvoxamine-Maleate-019005.aspx
Parchem	29006	http://www.parchem.com/chemical-supplier-distributor/Fluvoxamine-Maleate-019006.aspx
Selleck Chemicals	S1336	http://www.selleckchem.com/products/Fluvoxamine-maleate.html
Sigma-Aldrich	1285909_USP	https://www.sigmaaldrich.com/catalog/product/usp/1285909?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP600_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp600?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	F-040_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/f040?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	F2802_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/f2802?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1793_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1793?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S528235	http://www.smolecule.com/products/s528235
TCI (Tokyo Chemical Industry)	F0858	http://www.tcichemicals.com/eshop/en/us/commodity/F0858/index.html
THE BioTek	bt-268456	https://www.thebiotek.com/product/inhibitors/bt-268456
Tocris	1033	https://www.tocris.com/products/fluvoxamine-maleate_1033
VladaChem	VL272732-1G	https://www.vladachem.com/product.php?products=61718-82-9

PubMed

Title	Date	PubMed
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Pharmacological characterization and visualization of the glial serotonin transporter.	2001-07	11311448
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.	1997-12-11	9537821

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Obsessive Compulsive Disorder Initial extended release capsule dose: 100 mg orally once a day at bedtime Initial immediate release tablet dose: 50 mg orally once a day at bedtime Maintenance dose: 100 to 300 mg orally per day. The dose may be increased in 50 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved. Maximum Dose: 300 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

In the presence of 100 uM fluvoxamine, Kir4.1 currents heterologously expressed in HEK293T cells gradually increased during a hyperpolarizing step to −110 mV, and the outward current decreased rapidly during a depolarizing step to +30 mV

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:29:46 GMT 2025` Edited by `admin` on `Mon Mar 31 21:29:46 GMT 2025`
Record UNII	4E72PH61HL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUVOXAMINE, (Z)-

Common Name

English

(Z) FLUVOXAMINE

Preferred Name

English

FLUVOXAMINE MALEATE IMPURITY, Z-ISOMER- [USP IMPURITY]

Common Name

English

1-PENTANONE, 5-METHOXY-1-(4-(TRIFLUOROMETHYL)PHENYL)-, O-(2-AMINOETHYL)OXIME, (1Z)-

Common Name

English

FLUVOXAMINE MALEATE IMPURITY B [EP IMPURITY]

Common Name

English

2-((((1Z)-5-METHOXY-1-(4-(TRIFLUOROMETHYL)PHENYL)PENTYLIDENE)AMINO)OXY)ETHANAMINE

Systematic Name

English

Code System Code Type Description

CAS

89035-92-7

Created by admin on Mon Mar 31 21:29:46 GMT 2025 , Edited by admin on Mon Mar 31 21:29:46 GMT 2025

PRIMARY

EPA CompTox

DTXSID60237496

Created by admin on Mon Mar 31 21:29:46 GMT 2025 , Edited by admin on Mon Mar 31 21:29:46 GMT 2025

PRIMARY

PUBCHEM

5361192

Created by admin on Mon Mar 31 21:29:46 GMT 2025 , Edited by admin on Mon Mar 31 21:29:46 GMT 2025

PRIMARY

FDA UNII

4E72PH61HL

Created by admin on Mon Mar 31 21:29:46 GMT 2025 , Edited by admin on Mon Mar 31 21:29:46 GMT 2025

PRIMARY

Related Record Type Details


					5LGN83G74V

FLUVOXAMINE MALEATE

PARENT -> IMPURITY

AE	Significance	Dose	Population
Fatigue	grade 3 Disc. AE	5.5 g single, oral Overdose Dose: 5.5 g Route: oral Route: single Dose: 5.5 g Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/
Sinus bradycardia	grade 3 Disc. AE	5.5 g single, oral Overdose Dose: 5.5 g Route: oral Route: single Dose: 5.5 g Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7804678/
Drowsiness	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
Cardiac arrest	Disc. AE	9.6 g single, oral Overdose Dose: 9.6 g Route: oral Route: single Dose: 9.6 g Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/
Status epilepticus	Disc. AE	9.6 g single, oral Overdose Dose: 9.6 g Route: oral Route: single Dose: 9.6 g Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17952747/
Abdominal pain	Disc. AE	4800 mg single, oral Overdose Dose: 4800 mg Route: oral Route: single Dose: 4800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
Diarrhoea	Disc. AE	4800 mg single, oral Overdose Dose: 4800 mg Route: oral Route: single Dose: 4800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
Nausea	Disc. AE	4800 mg single, oral Overdose Dose: 4800 mg Route: oral Route: single Dose: 4800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7906658/
Nausea	2.6% Disc. AE	100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16160624/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16160624/
Serotonin syndrome	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Suicidal behavior	Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Status epilepticus		9.6 g single, oral Overdose Dose: 9.6 g Route: oral Route: single Dose: 9.6 g Sources: https://pubmed.ncbi.nlm.nih.gov/17952747	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/17952747
Abdominal pain		4.8 g single, oral Overdose Dose: 4.8 g Route: oral Route: single Dose: 4.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/7906658
Diarrhoea		4.8 g single, oral Overdose Dose: 4.8 g Route: oral Route: single Dose: 4.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/7906658
Nausea		4.8 g single, oral Overdose Dose: 4.8 g Route: oral Route: single Dose: 4.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7906658	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/7906658
Hypomania		300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Hyponatremia	Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Seizures	Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Serotonin syndrome	Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Suicidal ideation	Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Agitation	2% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Asthenia	2% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Dizziness	2% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Nervousness	2% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Vomiting	2% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Headache	3% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Insomnia	4% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Somnolence	4% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf
Nausea	9% Disc. AE	300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00176Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluvoxamine.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00176
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluvoxamine.html

C_max

T_1/2

F_unbound

Drug as perpetrator